Biz: An acquisition pays off in the form of a landmark cancer drug
- $500 million The amount French drugmaker Sanofi-Aventis SA paid for BiPar Sciences Inc. of San Francisco, which has just 18 employees
- six weeks after the acquisition, a study came out showing that BiPar’s experimental drug helps immensely in fighting breast cancer source